Tramadol and flurbiprofen depress the cytotoxicity of cisplatin via their effects on gap junctions

Clinical Cancer Research

Volumn 15, Issue 18, 2009, Pages 5803-5810

  He, Bo ^a,b   Tong, Xuhui ^a   Wang, Lingzhi ^a   Wang, Qin ^a   Ye, Hua ^b   Liu, Bing ^a   Hong, Xiaoting ^a   Tao, Liang ^a   Harris, Andrew L ^c  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

18ALPHA GLYCYRRHETINIC ACID; CISPLATIN; CONNEXIN 32; DYE; FLURBIPROFEN; MORPHINE; TRAMADOL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL DESTRUCTION; CARCINOMA CELL; CELL ASSAY; CELL CULTURE; CELL DENSITY; CELL FUNCTION; CELL SURVIVAL; CLONOGENESIS; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EXPOSURE; DRUG INHIBITION; GAP JUNCTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CELL SURVIVAL; CISPLATIN; FLURBIPROFEN; GAP JUNCTIONS; GLYCYRRHETINIC ACID; HELA CELLS; HUMANS; TRAMADOL;

EID: 70349466804     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-0811     Document Type: Article

References (50)

1. Myers J, Shetty N. Going beyond efficacy: strategies for cancer pain management. Curr Oncol 2008;15:S41-9.
2. Cleary JF. The pharmacologic management of cancer pain. J Palliat Med 2007;10:1369-1394
3. Zamble DB, Lippard SJ. Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem Sci 1995;20:435-439
4. Eastman A. The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacol Ther 1987;34:155-166 (Pubitemid 17149009)
5. Chvalova K, Brabec V, Kasparkova J. Mechanism of the formation of DNA-protein cross-links by antitumor cisplatin. Nucleic Acids Res 2007;35:1812-1821 (Pubitemid 47061652)
6. Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 2008;73:994-1007. (Pubitemid 351543900)
7. Willecke K, Eiberger J, Degen J, et al. Structural and functional diversity of connexin genes in the mouse and human genome. Biol Chem 2002;383:725-737 (Pubitemid 34649891)
8. Mesnil M, Crespin S, Avanzo JL, Zaidan-Dagli ML. Defective gapju nctional intercellular communication in the carcinogenic process. Biochim Biophys Acta 2005;1719:125-145 (Pubitemid 41785641)
9. Prochazka L, Turanek J, Tesarik R, et al. Apoptosis and inhibition of gap-junctional intercellular communication induced by LA-12, a novel hydrophobic platinum(IV) complex. Arch Biochem Biophys 2007;462:54-61. (Pubitemid 46755141)
10. Trosko JE, Chang CC. Mechanism of up-regulated gapjunctional intercellular communication during chemoprevention and chemotherapy of cancer. Mutat Res 2001;480-481:219-229
11. Jensen R, Glazer PM. Cell-interdependent cisplatin killing by Ku/DNA-dependent protein kinase signaling transduced through gap junctions. Proc Natl Acad Sci U S A 2004;101:6134-6139 (Pubitemid 38520540)
12. Huang RP, Hossain MZ, Huang R, Gano J, Fan Y, Boynton AL. Connexin 43 (cx43) enhances chemotherapy-induced apoptosis in human glioblastoma cells. Int J Cancer 2001;92:130-138 (Pubitemid 32187042)
13. Tanaka M, Grossman HB. Connexin 26 gene therapy of human bladder cancer: induction of growth suppression, apoptosis, and synergy with Cisplatin. Hum Gene Ther 2001;12:2225-2236 (Pubitemid 34075186)
14. Wang M, Berthoud VM, Beyer EC. Connexin43 increases the sensitivity of prostate cancer cells to TNFα-induced apoptosis. J Cell Sci 2007;120:320-329 (Pubitemid 46243249)
15. Azzam EI, de Toledo SM, Little JB. Oxidative metabolism, gapjunctions and the ionizing radiation-induced bystander effect. Oncogene 2003;22:7050-7057
16. Pitts JD. Cancer gene therapy: a bystander effect using the gapjunctional pathway. Mol Carcinog 1994;11:127-130 (Pubitemid 24372803)
17. Mesnil M, Yamasaki H. Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: role of gap-junctional intercellular communication. Cancer Res 2000;60:3989-3999 (Pubitemid 30636571)
18. Koreen IV, Elsayed WA, Liu YJ, Harris AL. Tetracycline-regulated expression enables purification and functional analysis of recombinant connexin channels from mammalian cells. Biochem J 2004;383:111-119
19. Goldberg GS, Bechberger JF, Naus CC. A pre-loading method of evaluating gapj unctional communication by fluorescent dye transfer. Biotechniques 1995;18:490-497
20. Erdlenbruch B, Nier M, Kern W, Hiddemann W, Pekrun A, Lakomek M. Pharmacokinetics of cisplatin and relation to nephrotoxicity in paediatric patients. Eur J Clin Pharmacol 2001;57:393-402. (Pubitemid 33787190)
21. Davidson JS, Baumgarten IM. Glycyrrhetinic acid derivatives: a novel class of inhibitors of gap-junctional intercellular communication. Structure-activity relationships. J Pharmacol Exp Ther 1988;246:1104-1107
22. Jellinek H, Haumer H, Grubhofer G, et al. Tramadol in postoperative pain therapy. Patient-controlled analgesia versus continuous infusion. Anaesthesist 1990;39:513-520
23. Neumann PB, Henriksen H, Grosman N, Christensen CB. Plasma morphine concentrations during chronic oral administration in patients with cancer pain. Pain 1982;13:247-252 (Pubitemid 12092597)
24. Swede H, Mirand AL, Menezes RJ, Moysich KB. Association of regular aspirin use and breast cancer risk. Oncology 2005;68:40-47 (Pubitemid 40675007)
25. Harris RE, Chlebowski RT, Jackson RD, et al. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res 2003;63:6096-6101
26. Ammerpohl O, Trauzold A, Schniewind B, et al. Complementary effects of HDAC inhibitor 4-PB on gapjunction communication and cellular export mechanisms support restoration of chemosensitivity of PDAC cells. Br J Cancer 2007;96:73-81. (Pubitemid 46094642)
27. Wu YJ, Muldoon LL, Neuwelt EA. The chemoprotective agent N-acetylcysteine blocks cisplatin-induced apoptosis through caspase signaling pathway. J Pharmacol Exp Ther 2005;312:424-431
28. Lumniczky K, Safrany G. Cancer gene therapy: combination with radiation therapy and the role of bystander cell killing in the anti-tumor effect. Pathol Oncol Res 2006;12:118-124 (Pubitemid 44197182)
29. Dayer P, Desmeules J, Collart L. Pharmacology of tramadol. Drugs 1997;53 Suppl 2:18-24.
30. Driessen B, Reimann W. Interaction of the central analgesic, tramadol, with the uptake and release of 5-hydroxytryptamine in the rat brain in vitro. Br J Pharmacol 1992;105:147-151
31. Frink MC, Hennies HH, Englberger W, Haurand M, Wilffert B. Influence of tramadol on neurotransmitter systems of the rat brain. Arzneimittelforschung 1996;46:1029-1036 (Pubitemid 26391736)
32. Melikian HE, McDonald JK, Gu H, Rudnick G, Moore KR, Blakely RD. Human norepinephrine transporter. Biosynthetic studies using a site-directed polyclonal antibody. J Biol Chem 1994; 269:12290-12297 (Pubitemid 24196735)
33. Agnel M, Esnaud H, Langer SZ, Graham D. Pharmacological characterization of the cloned human 5-hydroxytryptamine transporter. Biochem Pharmacol 1996;51:1145-1151 (Pubitemid 26130405)
34. Du GJ, Lin HH, Xu QT, Wang MW. Bcl-2 switches the type of demise from apoptosis to necrosis via cyclooxygenase-2 upregulation in HeLa cell induced by hydrogen peroxide. Cancer Lett 2006;232:179-188
35. Husoy T, Knutsen HK, Cruciani V, et al. Connexin43 is overexpressed in Apc(Min/+)-mice adenomas and colocalises with COX-2 in myofibroblasts. Int J Cancer 2005;116:351-358 (Pubitemid 40993330)
36. Eisinger DA, Schulz R. Mechanism and consequences of δ-opioid receptor internalization. Crit Rev Neurobiol 2005;17:1-26.
37. Gioannini TL, Yao YH, Hiller JM, Taylor LP, Simon EJ. Antisera against peptides derived from a purified μ-opioid binding protein recognize the protein as well as μ-opioid receptors in brain regions and a cell line. Mol Pharmacol 1993;44:796-801.
38. Hanani M, Huang TY, Cherkas PS, Ledda M, Pannese E. Glial cell plasticity in sensory ganglia induced by nerve damage. Neuroscience 2002;114:279-283 (Pubitemid 35245408)
39. Lin SH, Lu CY, Muhammad R, et al. Induction of connexin 37 expression in a rat model of neuropathic pain. Brain Res Mol Brain Res 2002;99:134-140 (Pubitemid 34442229)
40. Ohara PT, Vit JP, Bhargava A, Jasmin L. Evidence for a role of connexin 43 in trigeminal pain using RNA interference in vivo. J Neurophysiol 2008;100:3064-3073
41. Lan L, Yuan H, Duan L, et al. Blocking the glial function suppresses subcutaneous formalin-induced nociceptive behavior in the rat. Neurosci Res 2007;57:112-119 (Pubitemid 46073248)
42. Spataro LE, Sloane EM, Milligan ED, et al. Spinal gap junctions: potential involvement in pain facilitation. J Pain 2004;5:392-405.
43. Mantz J, Cordier J, Giaume C. Effects of general anesthetics on intercellular communications mediated by gapjunc tions between astrocytes in primary culture. Anesthesiology 1993;78:892-901. (Pubitemid 23141365)
44. Ajmone-Cat MA, Nicolini A, Minghetti L. Differential effects of the nonsteroidal antiinflammatory drug flurbiprofen and its nitric oxide-releasing derivative, nitroflurbiprofen, on prostaglandin E (2), interleukin-1β, and nitric oxide synthesis by activated microglia. J Neurosci Res 2001;66:715-722
45. Santini G, Sciulli MG, Panara MR, et al. Effects of flurbiprofen and flurbinitroxybutylester on prostaglandin endoperoxide synthases. Eur J Pharmacol 1996;316:65-72. (Pubitemid 26426931)
46. Harris RE. Cyclooxygenase-2 (cox-2) and the inflammogenesis of cancer. Subcell Biochem 2007;42:93-126.
47. Fosslien E. Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lab Sci 2000;37:431-502. (Pubitemid 32173442)
48. Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 2001;15:2057-2072
49. Spugnini EP, Cardillo I, Verdina A, et al. Piroxicam and cisplatin in a mouse model of peritoneal mesothelioma. Clin Cancer Res 2006;12:6133-6143 (Pubitemid 44703779)
50. Duffy CP, Elliott CJ, O'Connor RA, et al. Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs (NSAIDs). Eur J Cancer 1998;34:1250-1259